Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Egetis Therapeutics in connection with a combined financing comprising an equity private placement and debt financing
Mandate

Vinge has advised Egetis Therapeutics in connection with a combined financing comprising an equity private placement and debt financing

October 13, 2023 Banking and Finance Capital Markets and Public M&A

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a combined financing comprising a SEK 172 million equity private placement and a SEK 290 million debt financing.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Lorin Arabi and Isabell Bitar (Capital Markets and Public M&A) and of Albert Wållgren, Arvid Weimers and Ida Redander (Banking and finance).

Related

Vinge has advised Gamma Waves on Sportway’s EUR 20 million financing round

 Vinge has acted as legal adviser to Gamma Waves in connection with Sportway’s EUR 20 million financing round. The round was led by Gamma Waves, together with continued participation from existing shareholders, and values Sportway at approximately EUR 92 million (around SEK 1 billion) post-money.
June 24, 2026

Vinge advises Spotlight Group in connection with offer from Kriptown

 Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group
June 17, 2026

Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)

 Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of series B in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 15 June 2026.
June 16, 2026